Tải bản đầy đủ - 0trang
Reteplase - Formulation and Format (61)
Reteplase, a recombinant plasminogen activator
The purity of reteplase, determined by hgh resolution chromatographic
methods (Rp-HPLC and SE-HPLC) is as follows:
Reteplase protein makes up > 99.99% of the total protein.
E. coli protein
ETthrina trypsin irhbitor < 2 ppm
Endotoxins< 5 E U / d
Reteplase is poorly soluble in water and the usual buffers, and requires the
addition of stabilizers (e.g. amino acids such as argtnine).
Absorption spectra (visible, UV, IR)
The protein concentration is determined by measurement of the absorption
at 280 nm against the respective buffer as reference. With a light path of 1 cm
and a protein concentration of 1 m g M , the absorbance is 1.69.
Isoelectric point (IEP)
The IEP of reteplase calculated from the amino acid composition is 7.23
The pH of the reconstituted medicinal product of reteplase is in the range
pH 7.0 to pH 7.4
If stored in the original package, the injection vials of reteplase 10 U are
stable for two years at temperatures of 2°C to 25°C. During prolonged
storage the powder should be protected from excessive exposure to light.
The lyophilisate is also stable if deep-frozen. Exposure to temperatures
above 25°C shortens the shelf-life; temperatures greater than 30°C should
After reconstitution as directed, the solution should be used immediately.
The reconstituted solution is chemically stable for 4 hours.
Dr Michael Waller and Dr Ulrich Kohnert
Nature and risk of the decomposition products
Decomposition results in transition to the two-chain form of reteplase.
Reteplase is presented as a sterile, dry, white, lyophilized powder in a
glass vial, mostly adhering to the glass wall of the vial.
Each vial contains 1.16 g powder, equivalent to 10 U (a single dose) of
Each dose of the medxinal product contains 1.O mg polysorbate 20, plus
871.0 mg arginine and 268.6 mg phosphoric acid as stabilizers.
The powder is reconstituted with 10 ml diluent (water) for intravenous
The potency of reteplase is gven in units (U) based on a reference
standard which is reteplase-specific and is not comparable with the units used
for other thrombolytic agents. The designation Mu (1 MU = 1 U) is also
sometimes used in publications.
Ulrich Kohnert was the Project Leader Biotechnology for the development
of reteplase. He is a chemist by training and has special expertise in in vitro
folding, purification and in vitro characterization of proteins, as well as the
development of pharmaceutical formulations for therapeutic proteins.
Boehringer Mannheim is a htgh technology company in the healthcare market.
It holds a leading position in research development and production of
diagnostics and new drugs. Biotechnology has a prominent position and long
tradition withtn the company profile. Boehringer Mannheim operates one of
Europe's largest biotechnology facilities in Penzberg, Bavaria. Boehringer
Mannheim GmbH is part of the Roche Deutschland Holding GmbH.
Reteplase, a recombinant plasminogen activator
1. Gruppo Italian0 per lo Studio della Streptochinasi nell’hfarto miocardico (GISSI).
(1986). Effectiveness of intravenous thrombolytic treatment in acute myocardial
infarction. Lancet, 1, 871-874.
2. ISIS-2 (second International Study of Infarct Survival ) Collaborative Group. (1988).
Randomised trial of intravenous streptokinase, oral aspirin, both or neither among
17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2, 349-360.
3. ISAM Study Group. (1986). A prospective trial of intravenous streptokinase in acute
myocardial infarction (ISAM). N. Engl. J. Med., 314, 1465-1471.
4. AIMS Trial Study Group. (1988). Effect of intravenous APSAC on mortality after acute
myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet,
5 . Wilcox, R.G. et al. (1988). Trial oftissue plasminogen activator for mortality reduction
in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis
(ASSET). Lancet, 2, 525-530.
6. White, H.D. et al. (1987). Effect of intravenous streptokinase on left ventricular function
and early survival after acute myocardial infarction. N. Engl. J. Med., 317, 850-855.
7. Van De Werf, F. and Arnold, A.E.R. (1988). Intravenous tissue plasminogen activator
and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Br. Med. J., 297, 1374-1379.
8. GUSTO-Angiographic Investigators. (1993). The effects of tissue plasminogen activator,
streptokinase or both on coronary-artery patency, ventricular function and survival after
acute myocardial infarction. N. Engl. J. Med., 1329, 1615-1622.
9. Granger, C.B. et al. (1992). Thrombolytic therapy for acute myocardial infarction - a
review. Drugs, 44, 293-325.
10. Sobel, B.E. and Collen, D. (1992). Questions unresolved by the Third International
Study ofhfarct Survival. Am. J. Cardiol., 70, 385-389.
11. Bode, C. et al. (1997). Clinical trial results with a new plasminogen activator. European
Heart Journal, 18 (suppl F), F17-F21.
12. Kohnert, U. et al. (1992). Biochemical properties of the kringle 2 and protease domains
are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng., 5, 93-100.
13. Martin, U. et al. (1993). BM 06.022: A novel recombinant plasmhogen activator.
Cardiovasc. Drug Rev., 11, 299-3 11.
14. Braunwald, E. (1987). The path to myocardial salvage by thrombolytic therapy.
Circulation, 76(suppl II), 11-2 - II7.
15. Chazov, E.I. et al. (1976). Intracoronary administration of fibrinolysis in acute
myocardial infarction. Ter Arkh, 48, 8.
16. Rentrop, K.T. et al. (1979). Initial experience with transluminal recanalization of the
recently occluded infarct-related coronary artery in acute myocardial infarction.
Comparison with conventionally treated patients. Clin. Cardiol., 2, 92.
17. Blumgart, H.L. et al. (1941). Experimental studies on the effect of temporary occlusion
of coronary arteries. Am. J. Heart., 22, 374-389.
18. Smalling, R.W. and Hanna, G.P. (1966). Clinical pharmacology and mechanisms of
action of thrombolytic agents. In: CalBRM (ed.). Thrombolytic Therapy: New
Standards of Care, Part I: the Science of Plasminogen Activators. American Journal of
Cardiology. Belle Mead, NJ: Excerpta Medica, 9-15.
19. The GUSTO Investigators (1993). An international randomized trial comparing four
thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med., 329, 673-682.
Dr Michael WalIer and Dr Ulrich Kohnert
20. Rapaport, E.(1992). The ideal thrombolytic agent. In: Sleight P, Tavavi L (eds). The
Major Clinical Trials on Thrombolysis for Acute Myocardial Infarction. New York:
Raven Press, 1-5.
21. Vahanian, A. (1996). Thrombolytic therapy in Europe: current status. Eur. Heart J.,
22. S h e s , R.J. et al. (1995). Link between the angiographic substudy and mortality
outcomes in a large randomized trial of myocardial reperfusion: Importance of early and
complete artery reperfusion. Circulation, 91, 1923-1928.
23. Fischer, S . (1998). The molecular design of reteplase. Drugs of Today, 33, 641-648.
24. Bode, C. et al. (1996). The future of thrombolysis in the treatment of acute myocardial
infarction. Eur. Heart J., 17(suppl E), 55-60.
25. Fischer, S.and Kohnert, U. (1997). Major mechanistic differences explain the higher
clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for
bolus application of fibrin-specific thrombolytics. Fibrinolysis and Proteolysis, 11(3),
26. Pennica, D. et al. (1983). Cloning and expression of human tissue-type plasminogen
activator cDNA in E. coli. Nature, 301, 214-221.
27. S m a h g , R.W. (1996). Molecular biology of plasminogen activators: What are the
clinical implications of drug design? Am. J. Cardiol., 78 (suppl 12A), 2-7.
28. Hotchkiss, A. et al. (1988). The influence of carbohydrate structure on the clearance of
recombinant tissue-type plasminogen activator. Thromb. Haemost., 60, 255-261.
29. Kohnert, U.et al. (1993). A variant tissue plasminogen activator (t-PA) comprised of
the kringle 2 and protease domain shows a significant difference in the in vitro rate of
plasmin formation as compared to the recombinant human t-PA fiom transformed
Chinese hamster ovary cells. Fibrinolysis, 7, 365-372.
30. Sprengers, E.D. and KIuft, C. (1987). Plasmhogen activator inhibitors. Blood, 69, 381387.
31. Ny, T. et al. (1984). The structure of the human tissue-type plasminogen activator gene:
correlation of intron and exon structures to functional and structural domains. Proc.
Natl. Acad. Sci., 81, 5355-5359.
32. Stem, A. et al. (1990). Gewebs-Plasminogenaktivator-Derivat. European Patent
33. Maniatis, T. et al. (1992). Molecular Cloning: A Laboratory Manual. Cold Spring
Harbor, NY: Cold Spring Earbor Laboratory Press.
34. Brinkmann, U. et aZ. (1989). High-level expression of recombinant genes in
Escherichia coli is dependent on the availability of the dnaY gene product. Gene, 85,
35. Rudolph, R. et al. (1987). Verfahren zur Aktiviemg von gentechnologisch
hergestellten, heterologen, Disulfidbriicken aufweisenden eukaryontischen Proteinen
nach Expression in Prokaryonten. European Patent Application 219874.
36. Rudolph, R. (1990). In: Tschesche H (ed.). Modem Methods in Protein and Nucleic
Acid Research. Berlin: Walter de Gruyter, 149-172.
37. Rudolph, R. and Fischer, S. (1990). Process for obtaining renatured proteins. United
States Patent, 4933434.
38. Heussen, C. et al. (1984). Purification of human tissue plasminogen activator with
EIythrina trypsin mhibitor. J. Biol. Chem., 259, 11635-11638.
39. Kruithof, E.K. et al. (1985). Human tissue-type plasminogen activator. Production in
continuous serum-free cell culture and rapid purification. Biochem. J., 226, 63 1-636.
Reteplme, a recombinant plasminogen activator
40. Verheijen, J.H. et al. (1982). A simple spectrophotometric assay for extrinsic (tissuetype) plasminogen activator applicable to measurements in plasma. Thromb.
Haemostas., 48(3), 266-269.
41. Kohnert, U. et al. (1996). The recombinant Escherichia coli-derived protease-domain of
tissue-type plasminogen activator is a potent and fibrin specifc fibrinolytic agent.
Fibrinolysis, 10, 83-102.
42. Martin, U. et al. (1992). Evaluation of thrombolytic and systemic effects of novel
recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase,
streptokinase and urokinase in a canine model of coronary artery thrombosis. J. Am.
Coll. Cardiol., 19, 433-440.
43. Martin, U. et al. (1992). Hirudin and sulotroban improve coronary blood flow after
reperfhion induced by the novel recombinant plasminogen activator BM 06.022 in a
canine model of coronary artery thrombosis. Int. J. Hematol., 56, 143-153.
44. Martin, U. et al. (1991). Pharmacokinetic properties of an Escherichia coli-produced
recombinant plasminogen activator (BM 06.022) in rabbits. Thromb. Res., 62, 137-146.
45. Martin, U. et al. (1992). Pharmacokinetics ofthe novel recombinant plasminogen
activator BM 06.022 in rats, dogs and non-human primates. Fibrinolysis, 6, 39-43.
46. Martin, U. et al. (1991). Dose-ranging study of the novel recombinant plasminogen
activator BM 06.022 in healthy volunteers. Clin. Pharmacol. Ther., 50, 429-436.
47. Seiiiied, E. et al. (1988). Pharmacokinetics of antigen and activity of recombinant
tissue-type plasminogen activator after infusion in healthy volunteers. Drug Res., 38,
48. Seifkied, E. et al. (1992). Bolus application of a novel recombinant plasminogen
activator in acute myocardial infarction patients: Pharmacokinetics and effects on the
hemostatic system. Ann.N.Y. Acad. Sci., 667, 417-420.
49. Tebbe, U. et al. (1989). Single bolus injection of recombinant tissue-type plasminogen
activator in acute myocardial infarction. Am. J. Cardiol., 64, 448-453.
50. Martin, U. et al. (1991). Pharmacokinetic and hemostatic properties of the recombinant
plasminogen activator BM 06.022 in healthy volunteers. Thromb. Haemost., 66(5), 569574.
5 1. Neuhau,s K-L. et al. (1994). Dose finding with a novel recombinant plasminogen
activator (BM 06.022) in patients with acute myocardial infarction: Results ofthe
German recombinant plasminogen activator study. J. Am. Coll. Cardiol., 24, 55-60.
52. Tebbe, U. et al. (1993). Open, noncontrolled dose-finding study with a novel
recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with
acute myocardial infarction. Am. J. Cardiol.,72, 5 18-524.
53. Griinewald, M. et al. (1995). Single vs double bolus thrombolysis with the recombinant
plasminogen activator BM 06.022 in patients with acute myocardial infarction pharmacokinetics and hemostatic changes (abstract). Thromb. Haemost., 73, 1328.
54. Smalling, R.W. et al. (1995). More rapid, complete, and stable coronary thrombolysis
with bolus administration of reteplase compared with alteplase infusion in acute
myocardial infarction. Circulation, 91, 2725-2732.
55. Bode, C. et al. (1996). Randomized comparison of coronary thrombolysis achieved with
a double-bolus reteplase (recombinant plasminogen activator) and fiont-loaded,
accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute
myocardial infarction. Circulation, 94, 891-898.
56. International Joint Efficacy Comparison of Thrombolytics. (1995). Randomised, doubleblind comparison of reteplase double-bolus administration with streptokinase in acute
myocardial infarction (INJECT): trial to investigate equivalence. Lancet, 346, 329-336.
Dr Michael Waller and Dr Ulrich Kohnert
57. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III)
Investigators. (1997). A comparison of reteplase with alteplase for acute myocardial
infarction N. Ehg.1 J. Med., 337, 1118-1123.
58. Chesebro, J.H. et al. (1987). Thrombolysis in Myocardial Infarction 0
I: A comparison between tissue plasminogen activator and intravenous streptokinase.
Clinical findings through hospital discharge. Circulation, 76, 142-154.
59. Schroder, R. et al. (1995). Extent of early ST segment elevation resolution: A strong
predictor of outcome in patients with acute myocardial infarction and a sensitive
measure to compare thrombolytic regimens. A substudy of the international joint
efficacy comparison ofthrombolytics (INJECT) trial. J. Am. Coll. Cardiol., 26, 16571664.
60. Schroder, R. et al. (1994). Extent of early ST segment elevation resolution: A simple
but strong predictor of outcome in patients with acute myocardial infarction. J. Am.
Coll. Cardiol., 24, 384-391.
61. Rapilysin: Reteplase. (1998). Standard Information for Hospital Pharmacists.